文献速递药疹与重症皮肤不良反应

在种族多样化人群中普遍筛查HLA-B*15:02是否具有成本效益?马来西亚案例研究

Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.
PubMed 文献 · Br J Dermatol · 2017-09-21

该研究采用决策树与Markov模型混合模型,评估马来西亚成人新诊断癫痫三种治疗策略的终身成本效益。结论认为在马来西亚普遍筛查不太可能具有成本效益。

要点

  • 在马来西亚,普遍筛查和丙戊酸处方均不具成本效益。

核心结论

  • 在马来西亚,普遍HLA-B*15:02筛查不太可能具有成本效益。
  • 随着许多国家人群种族多样化,当风险人群比例增加且存在同等有效更安全的抗癫痫药时,筛查可能可行。

研究设计与样本

  • 研究采用决策树与Markov模型的混合模型,评估马来西亚成人新诊断癫痫的三种治疗策略。
  • 分析时间范围为终身,进行了基础案例分析和敏感性分析,计算增量成本效果比。

临床怎么用

  • 在马来西亚,不建议普遍进行HLA-B*15:02筛查以预防卡马西平诱导的Stevens-Johnson综合征/中毒性表皮坏死松解症。
  • 临床决策需考虑人群种族构成和替代药物的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A strong association has been documented between HLA-B*15:02 and carbamazepine-induced severe cutaneous adverse reactions (SCARs) in Asians. Human leucocyte antigen testing is potentially valuable in many countries to facilitate early recognition of patient susceptibility to SCARs. OBJECTIVES: To determine the cost-effectiveness of universal HLA-B*15:02 screening in preventing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in an ethnically diverse Malaysian population. METHODS: A hybrid model of a decision tree and Markov model was developed to evaluate three strategies for treating newly diagnosed epilepsy among adults: (i) carbamazepine initiation without HLA-B*15:02 screening (current practice); (ii) universal HLA-B*15:02 screening prior to carbamazepine initiation; and (iii) alternative treatment [sodium valproate (VPA)] prescribing without HLA-B*15:02 screening. Base-case analysis and sensitivity analyses were performed over a lifetime time horizon. Incremental cost-effectiveness ratios were calculated. RESULTS: Both universal HLA-B*15:02 screening and VPA prescribing were dominated by current practice. Compared with current practice, universal HLA-B*15:02 screening resulted in a loss of 0·0255 quality-adjusted life years (QALYs) at an additional cost of 707 U.S. dollars (USD); VPA prescribing resulted in a loss of 0·2622 QALYs at an additional cost of USD 4127, owing to estimated differences in antiepileptic treatment efficacy. CONCLUSIONS: Universal HLA-B*15:02 screening is unlikely to be a cost-effective intervention in Malaysia. However, with the emergence of an ethnically diverse population in many other countries, this may render HLA-B*15:02 screening a viable intervention when an increasing proportion of the population is at risk and an equally effective yet safer antiepileptic drug is available.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Chong HY, Mohamed Z, Tan LL, et al. Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia. Br J Dermatol. 2017. PMID: 28346659. doi:10.1111/bjd.15498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。